Skip to content

A research of placenta extract in elderly people with low muscle strength and gait speed

A clinical study of the efficacy and safety of placenta extract in elderly people with low muscle strength and gait speed -Open label trial- - A research of placenta extract in elderly people with low muscle strength and gait speed

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000042240
Enrollment
30
Registered
2020-10-28
Start date
2017-08-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elderly people with low muscle strength and gait speed

Interventions

daily intake of test food containing 3 g of placenta extract for 12 weeks

Sponsors

Japan Bio Products Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Male and female over 65 years of age 2) Those whose grip strength is less than 30 kg for men and 20 kg for women. 3) Those whose gait speed is less than 1.2 m/sec. 4) A person who has obtained written consent 5) Patients with complications or pre-existing conditions that are stable and judged by the principal investigator to be eligible to participate in this clinical study.

Exclusion criteria

Exclusion criteria: 1)Persons with allergic symptoms to the test food and excipients 2) Persons with difficulty walking or with diseases that are known to affect their ability to move (known muscular disease, peripheral vascular disease causing intermittent claudication, central and peripheral nerve disease (e.g. Parkinson's disease, spinal cord disease, motor neuron disease, etc.), severe dementia, severe diabetes). 3) Any person with a history or suspicion of being affected by cachexia 4) Anyone taking a BCAA supplement. 5) Those who continue to take placenta extract 6) Those who have participated in another clinical trial within the past six months 7) A person who is judged by the principal investigator to be unsuitable to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
gait speed grip strength

Secondary

MeasureTime frame
calf circumference QOL score total testosterone DHEA-S IGF-1 adverse event laboratory examination

Countries

Japan

Contacts

Public ContactTomoya Mimura

Japan Bio Products Co., Ltd. Medical Affairs Department

t_mimura@placenta-jbp.co.jp03-3481-6061

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026